Prevention of endophthalmitis by collagen shields presoaked in fourth-generation fluoroquinolones versus by topical prophylaxis

Journal of Cataract and Refractive Surgery

Volumn 34, Issue 5, 2008, Pages 853-858

  Haugen, Brian ^a   Werner, Liliana ^a   Romaniv, Natalya ^a   Haymore, Jonathan ^a   Kleinmann, Guy ^a   Mamalis, Nick ^a   Olson, Randall J ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BALANCED SALT SOLUTION; COLLAGEN; GATIFLOXACIN; MOXIFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENDOPHTHALMITIS; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RABBIT; SLIT LAMP; STAPHYLOCOCCUS EPIDERMIDIS;

ADMINISTRATION, TOPICAL; ANIMALS; ANTERIOR CHAMBER; ANTI-INFECTIVE AGENTS; COLLAGEN; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; FEMALE; FLUOROQUINOLONES; MALE; OPHTHALMIC SOLUTIONS; RABBITS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS EPIDERMIDIS;

EID: 42949164965     PISSN: 08863350     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcrs.2008.01.011     Document Type: Article

References (23)

1. Han D.P., Wisniewski S.R., Wilson L.A., et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study Group. Am J Ophthalmol 122 (1996) 1-17 correction, 920
2. Mather R., Karenchak L.M., Romanowski E.G., and Kowalski R.P. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol 133 (2002) 463-466
3. Kowalski R.P., Dhaliwal D.K., Karenchak L.M., et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 136 (2003) 500-505
4. Miller D., Flynn P.M., Scott I.U., et al. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates. Arch Ophthalmol 124 (2006) 479-483
5. Moshirfar M., Feiz V., Vitale A.T., et al. Endophthalmitis after uncomplicated cataract surgery with the use of fourth-generation fluoroquinolones; a retrospective observational case series. Ophthalmology 114 (2007) 686-691
6. Levine J.M., Noecker R.J., Lane L.C., et al. Comparative penetration of moxifloxacin and gatifloxacin in rabbit aqueous humor after topical dosing. J Cataract Refract Surg 30 (2004) 2177-2182
7. Kim D.H., Stark W.J., O'Brien T.P., and Dick J.D. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Ophthalmology 112 (2005) 1992-1996
8. Solomon R., Donnenfeld E.D., Perry H.D., et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology 112 (2005) 466-469
9. McCulley J.P., Caudle D., Aronowicz J.D., and Shine W.E. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology 113 (2006) 955-959
10. Ong-Tone L. Aqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given by different methods before cataract surgery. J Cataract Refract Surg 33 (2007) 59-62
11. Hariprasad S.M., Blinder K.J., Shah G.K., et al. Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Arch Ophthalmol 123 (2005) 39-44
12. Hariprasad S.M., Mieler W.E., Shah G.K., et al. Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration. Trans Am Ophthalmol Soc 102 (2004) 149-155. http://www.aosonline.org/xactions/2004/1545-6110_v102_p149.pdf Accessed February 2, 2008
13. Hariprasad S.M., Shah G.K., Chi J., and Prince R.A. Determination of aqueous and vitreous concentration of moxifloxacin 0.5% after delivery via a dissolvable corneal collagen shield device. J Cataract Refract Surg 31 (2005) 2142-2146
14. Kleinmann G., Larson S., Neuhann I.M., et al. Intraocular concentrations of gatifloxacin and moxifloxacin in the anterior chamber via diffusion through the cornea using collagen shields. Cornea 25 (2006) 209-213
15. Kleinmann G., Larson S., Hunter B., et al. Collagen shields as a drug delivery system for the fourth-generation fluoroquinolones. Ophthalmologica 221 (2007) 51-56
16. Kowalski R.P., Romanowski E.G., Mah F.S., et al. Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model. Am J Ophthalmol 138 (2004) 33-37
17. Taban M., Behrens A., Newcomb R.L., et al. Acute endophthalmitis following cataract surgery; a systematic review of the literature. Arch Ophthalmol 123 (2005) 613-620
18. Javitt J.C., Vitale S., Canner J.K., et al. National outcomes of cataract extraction; endophthalmitis following inpatient surgery. Arch Ophthalmol 109 (1991) 1085-1089
19. Javitt J.C., Street D.A., Tielsch J.M., et al. National outcomes of cataract extraction: retinal detachment and endophthalmitis after outpatient cataract surgery; the Cataract Patient Outcomes Research Team. Ophthalmology 101 (1994) 100-105 discussion by PP Lee, 106
20. Jensen M.K., Fiscella R.G., Crandall A.S., et al. A retrospective study of endophthalmitis rates comparing quinolone antibiotics. Am J Ophthalmol 139 (2005) 141-148
21. Wallin T., Parker J., Jin Y., et al. Cohort study of 27 cases of endophthalmitis at a single institution. J Cataract Refract Surg 31 (2005) 735-741
22. Willoughby C.E., Batterbury M., and Kaye S.B. Collagen corneal shields. Surv Ophthalmol 47 (2002) 174-182
23. O'Brien T.P., Sawusch M.R., Dick J.D., et al. Use of collagen corneal shields versus soft contact lenses to enhance penetration of topical tobramycin. J Cataract Refract Surg 14 (1988) 505-507